GSK Gets Stung By First UK Pay-For-Delay Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Competition and Markets authority levies fines on GSK and two generics firms for agreement on paroxetine.
You may also be interested in...
UK Wants European Court's View On Paroxetine Pay-For-Delay Case
A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.
UK Wants European Court's View On Paroxetine Pay-For-Delay Case
A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.
Pharma Faces More Probes On Generic Price Hikes in UK
As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.